Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats

RW Fuller and KW Perry

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.

Buspirone, an anxiolytic drug with selective affinity for the 5-HT-1A subtype of serotonin receptors, caused a dose-related decrease in 5- hydroxyindole acetic acid (5-HIAA) concentration in rat hypothalamus after doses of 1 to 10 mg/kg s.c. The decrease in 5-HIAA concentration after a 3 mg/kg s.c. dose of buspirone persisted at 4 hr but not at 7 hr. The decrease was due apparently to a reduced turnover of serotonin; the accumulation of 5-hydroxytryptophan after decarboxylase inhibition was also suppressed by buspirone, not only in hypothalamus but also in brain stem, hippocampus and striatum. 1-(2-Pyrimidinyl)-piperazine (1- PP), a major metabolite of buspirone, did not affect hypothalamic 5- HIAA concentration at doses up to 10 mg/kg s.c. Both buspirone and 1-PP increased hypothalamic concentrations of 3-methoxy-4- hydroxyphenylethyleneglycol (MHPG) sulfate, the norepinephrine metabolite, the effect being more pronounced with 1-PP but occurring after doses as low as 0.3 mg/kg s.c. with each compound. The increase in MHPG sulfate concentration persisted for at least 4 hr after a 3 mg/kg s.c. dose of each compound. The increase in MHPG sulfate produced by buspirone may have been due partly to 5-HT-1A receptor activation, inasmuch as other serotonin agonists have been found to cause a similar increase. 1-PP is reported to lack affinity for 5-HT-1A receptors so its elevation of MHPG sulfate concentration may have resulted from alpha-2 receptor blockade. The increase in MHPG sulfate concentration after buspirone injection may have been due at least partly to formation of the metabolite, 1-PP.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 248, Issue 1, pp. 50-56, 01/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				K. Rasmussen, M.-A. Hsu, S. Noone, B. G. Johnson, L. K. Thompson, and S. K. Hemrick-Luecke The Orexin-1 Antagonist SB-334867 Blocks Antipsychotic Treatment Emergent Catalepsy: Implications for the Treatment of Extrapyramidal Symptoms Schizophr Bull, November 1, 2007; 33(6): 1291 - 1297. [Abstract] [Full Text] [PDF]

				K. Rasmussen, M. J. Benvenga, F. P. Bymaster, D. O. Calligaro, I. R. Cohen, J. F. Falcone, S. K. Hemrick-Luecke, F. M. Martin, N. A. Moore, L. K. Nisenbaum, et al. Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1265 - 1277. [Abstract] [Full Text] [PDF]

				L. Renyi, J. L. Evenden, C. J. Fowler, E. Jerning, D. Kelder, D. Lake-Bakaar, L.-G. Larsson, N. Mohell, M. Sallemark, and S. B. Ross The Pharmacological Profile of (R)-3,4-Dihydro-N-isopropyl-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran-5-carboxamide, a Selective 5-Hydroxytryptamine1A Receptor Agonist J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 883 - 893. [Abstract] [Full Text] [PDF]

				Y. Du, Z. Ma, S. Lin, R. C. Dodel, F. Gao, K. R. Bales, L. C. Triarhou, E. Chernet, K. W. Perry, D. L. G. Nelson, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease PNAS, November 20, 2001; (2001) 251341998. [Abstract] [Full Text] [PDF]

				M. L. Cohen, K. W. Schenck, and S. H. Hemrick-Luecke 5-Hydroxytryptamine1A Receptor Activation Enhances Norepinephrine Release from Nerves in the Rabbit Saphenous Vein J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1195 - 1201. [Abstract] [Full Text]

				D. R. Gehlert, L. Dreshfield, F. Tinsley, M. J. Benvenga, S. Gleason, R. W. Fuller, D. T. Wong, and S. K. Hemrick-Luecke The Selective Norepinephrine Reuptake Inhibitor, LY368975, Reduces Food Consumption in Animal Models of Feeding J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 122 - 127. [Abstract] [Full Text]

				H. E. Shannon, M. J. Sheardown, F. P. Bymaster, D. O. Calligaro, N. W. Delapp, J. Gidda, C. H. Mitch, B. D. Sawyer, P. W. Stengel, J. S. Ward, et al. Pharmacology of Butylthio[2.2.2] (LY297802/NNC11-1053): A Novel Analgesic with Mixed Muscarinic Receptor Agonist and Antagonist Activity J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 884 - 894. [Abstract] [Full Text]

				Y. Du, Z. Ma, S. Lin, R. C. Dodel, F. Gao, K. R. Bales, L. C. Triarhou, E. Chernet, K. W. Perry, D. L. G. Nelson, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease PNAS, December 4, 2001; 98(25): 14669 - 14674. [Abstract] [Full Text] [PDF]